{"name":"Mirum Pharmaceuticals","slug":"mirum","ticker":"MIRM","exchange":"NASDAQ","domain":"mirumpharma.com","description":"Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xant","hq":"Foster City, CA","founded":2018,"employees":"369","ceo":"Chris Peetz","sector":"Rare Hepatology","stockPrice":97.3,"stockChange":1.65,"stockChangePercent":1.73,"marketCap":"$5.9B","metrics":{"revenue":19138000,"revenueGrowth":49.8,"grossMargin":80.8,"rdSpend":0,"netIncome":-23363000,"cash":383327008,"dividendYield":0,"peRatio":-896.2,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2015-01-01","label":"Cholbam first approved","drug":"Cholbam","drugSlug":"cholic-acid","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"maralixibat patent cliff ($0.0B at risk)","drug":"maralixibat","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"volixibat patent cliff ($0.0B at risk)","drug":"volixibat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Cholbam","genericName":"CHOLIC ACID","slug":"cholic-acid","indication":"Bile Acid Synthesis Disorders Due to SEDs","status":"marketed"},{"name":"High dose of MRM-3379","genericName":"High dose of MRM-3379","slug":"high-dose-of-mrm-3379","indication":"Other","status":"phase_2"},{"name":"Livmarli","genericName":"Livmarli","slug":"livmarli","indication":"Cholestatic pruritus in patients with Alagille syndrome (ALGS)","status":"marketed"},{"name":"Livmarli Oral Product","genericName":"Livmarli Oral Product","slug":"livmarli-oral-product","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CDCA Weight-Based Dose TID","genericName":"CDCA Weight-Based Dose TID","slug":"cdca-weight-based-dose-tid","indication":"Progressive familial intrahepatic cholestasis (PFIC) type 1","status":"phase_3"},{"name":"Cholic Acids","genericName":"Cholic Acids","slug":"cholic-acids","indication":"Cerebrotendinous xanthomatosis (CTX)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Cholbam","genericName":"Cholbam","slug":"cholbam","indication":"3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency","status":"marketed"}]}],"pipeline":[{"name":"CDCA Weight-Based Dose TID","genericName":"CDCA Weight-Based Dose TID","slug":"cdca-weight-based-dose-tid","phase":"phase_3","mechanism":"CDCA (chenodeoxycholic acid) is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling to reduce bile acid synthesis and improve cholestasis.","indications":["Progressive familial intrahepatic cholestasis (PFIC) type 1","Progressive familial intrahepatic cholestasis (PFIC) type 2"],"catalyst":""},{"name":"Cholbam","genericName":"Cholbam","slug":"cholbam","phase":"marketed","mechanism":"G-protein coupled bile acid receptor 1, Bile acid receptor","indications":["3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency","Calculus in biliary tract","Cholestanol storage disease","Constipation","Delta-4-3-oxosteroid-5-beta-reductase deficiency"],"catalyst":""},{"name":"Cholbam","genericName":"CHOLIC ACID","slug":"cholic-acid","phase":"marketed","mechanism":"Cholbam works by binding to the G-protein coupled bile acid receptor 1, which helps regulate bile acid levels in the body.","indications":["Bile Acid Synthesis Disorders Due to SEDs","Adjunctive Treatment of Peroxisomal Disorders"],"catalyst":""},{"name":"Cholic Acids","genericName":"Cholic Acids","slug":"cholic-acids","phase":"phase_3","mechanism":"Cholic acid is a primary bile acid that restores bile acid-dependent signaling pathways to improve cholestasis and fat malabsorption in patients with bile acid synthesis disorders.","indications":["Cerebrotendinous xanthomatosis (CTX)","Progressive familial intrahepatic cholestasis (PFIC)","Bile acid synthesis disorders"],"catalyst":""},{"name":"High dose of MRM-3379","genericName":"High dose of MRM-3379","slug":"high-dose-of-mrm-3379","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Livmarli","genericName":"Livmarli","slug":"livmarli","phase":"marketed","mechanism":"Ileal sodium/bile acid cotransporter","indications":["Cholestatic pruritus in patients with Alagille syndrome (ALGS)"],"catalyst":""},{"name":"Livmarli Oral Product","genericName":"Livmarli Oral Product","slug":"livmarli-oral-product","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Mirum Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $44.5 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Mirum Pharmaceuticals Announces Collaboration with the National Institutes of Health (NIH) to Develop New Treatments for Rare Liver Diseases","summary":"Mirum Pharmaceuticals has entered into a collaboration with the NIH to develop new treatments for rare liver diseases, including Alagille syndrome and primary sclerosing cholangitis.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"regulatory","headline":"FDA Approves Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome","summary":"The FDA has approved maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeEY1aEZ1WGxwdU9HWVRKZHJtT2xFVlpiYjIzMkJ5RWNyWXBEdVMyU01GYmRXcTNoWHNmNEk2NDlHY3NFWjB3dFIwSEdUQ2ctZG9tUVZMU29hOG8yTXdoZzhYOWw1enRsaHoyaEo5S1FjTDZyWGdLa285X2w0RnQ4dlRUODVzR1JKNzlKdFRtUDJyTUFVeXJLTlR4OWVHWWNkelg4OHhVemRuQU9aRUlpZ3pJclZUbjQ0RjM1Tkxpbms?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"New Mirum hires get stock options at $91.75 in latest grants - Stock Titan","headline":"New Mirum hires get stock options at $91.75 in latest grants","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQeDVmOVFiblhUSHBYV25JU1F5bGtyeTEwb0VFUzltUE1RMnRUaUJhLVE2NDFGcERaa2JQQUJ1RUhmTFZrcUtHSW9Fem1ZQS1oVmpfSmVZYUhYRmZfTk9wYmgtUXFaNXdzNFlsTWZ1UFFjWjR6UVZ5RXFkZm1ncGtfekNudDdsT0VQZWt0SWNzTDNUbDVnak10OGFmWDlwdEdZR05CWXdNTDNSSXEtc21OSV9ObjFBRmJZTjJxZTQ0LV9NS2Nh?oc=5","date":"2026-02-23","type":"pipeline","source":"Business Wire","summary":"Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire","headline":"Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOOGhsYnY3cVhwOU1aVU1lVFhFMm5QSlJDUlNFTWgzbHRBVVdMb0dvQ0c3Q2VuV0puRTBPNTdPeWxncjJlaVhKRjFUSUlWc2d3WENBU0Q2VGVtQXNiOEUtV1o5NGhZcExITkhVaV9VWXdFT201a1lnM3RZbFJEdExYeFBsQ3hwVWtwU2hfd2Vibi03LUJJN0s3X0JpMjh6eGRWZmtUREtZYUNlVFZ5?oc=5","date":"2026-02-03","type":"pipeline","source":"Investing.com","summary":"Mirum Pharma CEO Peetz sells $941k in shares - Investing.com","headline":"Mirum Pharma CEO Peetz sells $941k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNejhNd3lELTBrRW1yVEpadFVPN2pUd1p4NlRDLXRsWkZWaXVTN1R3elJrX0FqVkRtUXVNdjlzMGc2dkFsckRBLWZqTXlwbzdXblRROTdodm1HTWp3YlBVQTQxYVRSNkZVOHdWWlBCSnVIX3U4S3lTRy1zTW5xaEtRaVNrc1hzRV9sX0paTzNYVmJGQzNRU3M5RU5ZaFZtcktKeEpRNExza2M3NEluOTRlY0ZR?oc=5","date":"2026-02-03","type":"pipeline","source":"Investing.com","summary":"Mirum Pharma president & COO sells $271k in stock - Investing.com","headline":"Mirum Pharma president & COO sells $271k in stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOc0k1SGZKTzBEWVgzZlEtQnFIdVZoY3lTQ1JiSHJsVWNuNmk3TjRJUnVCVnpwR0F2RjQxWS1sWlBPZzNab2prb0ZOaERsVGs0VG1vUEJhdmplMzl0dEZzR21zXzV2cXdsR2IxYk43RnFLeF85b2VZY1YyQzI0d0xPMw?oc=5","date":"2026-01-20","type":"deal","source":"Yahoo Finance","summary":"CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - Yahoo Finance","headline":"CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQQzNvRElISzY1ME5ELVRLUWFWeHhKVTh2NFhReVFEXzVYQzBzRG5RRlU5ZVdEdzdtRWdCelRJbHc3ZXdRWjE1ZzhGclVvSGVFR0sxd1RtZHI2SE41LVFLeVJqQ3o5N2FQVW9QRkVPeDIzMzY1cWNhMzhRZ1gxZi01TTY0VEFManVOQzdiWW1WSlRKalB1UGlN?oc=5","date":"2026-01-13","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum - Yahoo Finance","headline":"Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxON2NEY1JyZFI5SG1SVktPd20wUXFDZnhjVHc1ZnFEQmx2ekl1X3BCQWFTOWcwUndzaVcxSHFkbkt0Wi1nVWpYS25PakQ4aHo4eHV1ek45RXY3X00zTzZ4Qmo1M0dmRkR6SzV2ZFRwcU4yVURqYVd2YndrWVlUek5ZSkpRS2JHY0Q3WXdScktzdm5UeGx6MEdxOURLaVRqMTFzbUEzQjJJSkowaHF0eGhnQnh5Y18wbHJr?oc=5","date":"2025-12-23","type":"pipeline","source":"Investing.com","summary":"Mirum Pharma director Grey sells $3.9 million in stock - Investing.com","headline":"Mirum Pharma director Grey sells $3.9 million in stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQc3VQR1NrVVhDOC1WVkoxS0NZNE11dTVVVnNWRGNVWWlwWmFzb21meEx5NFVwZ1hZaERQMXlEUVRVa3hOQTdWdWp4TUo2Y1dMRy11UklELUt5eWg3T2s1TGtlX20tYmpqSFN2czVBV21RRHVRSU1QVFRrLW4tR01MWWNmMFdPMG1pZk5VS0tPTEMtaDlvaXRFbGRLTDZjU25vSVJTbmFrekxGNExTeDBvYkw4cVlxS1ZnNHdQVVJjUFpKVEMtTGRpU1d0TTFZc1VGR2Zaag?oc=5","date":"2025-12-19","type":"deal","source":"TechStock²","summary":"Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target - TechStock²","headline":"Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Tar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdnVsZXJacllkXzE5aDUwU3p2ZmRvN0lURGdBTWV2QXRyaVB6dEZOSHBuSjRwd2s4V2EyRHR2UkZwUU9RRS1lWlJhemc0R05TaGwxNFpmaXNpYWoxaGpyREY2VExHZkU0M0dOVWxUWE1QZ1kxVS1yNkp3WWlYa0VOTXJfc0FSdlR2RGxfZXZZeGVCLU5mOHp4bWJNbW9HNEFRc2s0Sk96VkY?oc=5","date":"2025-12-08","type":"deal","source":"Reuters","summary":"Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug - Reuters","headline":"Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOX0hVRlBUa0diREFxeVY5dXloQjVGUy1TNTVkSW1QeUtfRWw2U3otRVhGUE9mV0hEaXhKQ0ZDWUFac1l1SmtYRnprR0paME82czE4cDRjSXQ4Q2xvRl9QOC1iRl9FNE5wSDMxMkptSVFOQ1haMDRVUGEzX2JBN2ZmbU5Rc3NqRTgzZml3amx3N1h6NlhhZU1EVVllN0ZWR3ZZV1BIRTR3RGQ0SWhOSHBja3BkSWdtN2lnUERwSXV5OXFkS2sxWlFLazZnelhaRkRFRzZCU3Frc2dqSEJ0ZzhYTEVCMWEyZktZcGE2dFdMYXhmWVZKZmFVcmVhNEhMTnY3Y3VMbkVxbV95d1lVeGVEakxrMmlvdw?oc=5","date":"2025-12-08","type":"deal","source":"Business Wire","summary":"Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Business Wire","headline":"Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOV3VtdmpOdUoxb0V3M0k4RTVnOWk5LVdyVVJ3X1FLeVlZb3d3ZFBTdGNJSFZBV0Nwa0VBeFllczZGYXc3WnNuNnE2eUtzMkw0WUxiX2RhanhQemRiTG5EbWdKc1o1OHpyM3VCLUtVdldwM2FlMlFSVDJSTXFpdDNta2VYSzgyckgtR1NQZGhrVFdSMmc?oc=5","date":"2025-12-08","type":"deal","source":"The Pharma Letter","summary":"Mirum Pharma to acquire Bluejay Therapeutics - The Pharma Letter","headline":"Mirum Pharma to acquire Bluejay Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNTC1ENWhGX3pNbGJrUHRIN1lEZ1Zqd1ZHdmViNkdBOTQxZUNzSXo0RmhSVlcwWkdSLV9zWHFlNEZOY2NmbnBkQ0lYZ1YzYUpJMFFvMjFPYTd2MUZ4X2lwUVg2SUFFUWsxcE50RlMwTE9mV25EMzRPczdXVWdaTlFMZUZwTGE2WDVvY2xudkdMUWx1OHFqSEhBci1JcHZOUVlJV3NyZ3kwOWJfSjc0a040?oc=5","date":"2025-01-08","type":"deal","source":"Seeking Alpha","summary":"Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM) - Seeking Alpha","headline":"Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM)","sentiment":"neutral"}],"patents":[{"drugName":"maralixibat","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"volixibat","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":7,"phaseCounts":{"phase_3":2,"marketed":4,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Madrigal Pharmaceuticals","Pfizer","Gilead Sciences"],"therapeuticFocus":["Rare Hepatology"],"financials":{"source":"sec_edgar","revenue":19138000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":19138000,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-23363000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":842813000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":97.3,"previousClose":95.65,"fiftyTwoWeekHigh":109.28,"fiftyTwoWeekLow":36.88,"fiftyTwoWeekRange":"36.88 - 109.28","fiftyDayAverage":96.16,"twoHundredDayAverage":75.45,"beta":0.52,"enterpriseValue":5707800576,"forwardPE":-896.2,"priceToBook":16.05,"priceToSales":11.26,"enterpriseToRevenue":10.95,"enterpriseToEbitda":2707.68,"pegRatio":0,"ebitda":2108000,"ebitdaMargin":0.4,"freeCashflow":98558872,"operatingCashflow":55827000,"totalDebt":319452000,"debtToEquity":101.5,"currentRatio":2.67,"returnOnAssets":-1.8,"returnOnEquity":-8.6,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":11,"targetMeanPrice":125.36,"targetHighPrice":140,"targetLowPrice":95,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.3,"institutionHeldPercent":104.9,"sharesOutstanding":60341617,"floatShares":52434452,"sharesShort":7460121,"shortRatio":9.04,"shortPercentOfFloat":12.4,"epsTrailing":-0.47,"epsForward":-0.11,"revenuePerShare":10.38,"bookValue":6.06,"officers":[{"age":46,"name":"Mr. Christopher  Peetz","title":"CEO & Director"},{"age":47,"name":"Mr. Peter  Radovich M.B.A., Ph.D.","title":"COO & President"},{"age":65,"name":"Mr. Eric H. Bjerkholt M.B.A., M.S.","title":"Chief Financial Officer"},{"age":61,"name":"Dr. Joanne M. J. Quan M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Jean-Luc  Girardet Ph.D.","title":"Chief Technical Officer"},{"age":null,"name":"Mr. Andrew  McKibben","title":"Senior Vice President, Strategic Finance & Investor Relations"},{"age":58,"name":"Mr. Douglas T. Sheehy J.D.","title":"Chief Legal Officer"},{"age":null,"name":"Meredith  Kiernan","title":"Senior Director of Global Corporate Communications"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.mirumpharma.com","phone":"650 667 4085"}}